{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:22:31Z","timestamp":1791152551550,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.medmal.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T23:42:51Z","timestamp":1409182971000},"page":"449-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of hepatitis C: Perspectives"],"prefix":"10.1016","volume":"44","author":[{"given":"S.","family":"Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2014.07.015_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2458-9-34","article-title":"HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality","volume":"9","author":"Muhlberger","year":"2009","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.medmal.2014.07.015_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","article-title":"Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study","volume":"53","author":"Omland","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.medmal.2014.07.015_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","article-title":"The changing epidemiology of hepatitis C virus infection in Europe","volume":"48","author":"Esteban","year":"2008","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.medmal.2014.07.015_bib0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.medmal.2014.07.015_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(00)02434-X","article-title":"Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa","volume":"356","author":"Fontaine","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2014.07.015_bib0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"Mchutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.medmal.2014.07.015_bib0040","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.medmal.2014.07.015_bib0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.medmal.2014.07.015_bib0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.medmal.2014.07.015_bib0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.medmal.2014.07.015_bib0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"suppl.","key":"10.1016\/j.medmal.2014.07.015_bib0065","first-page":"16","article-title":"New targets for antiviral therapy of chronic hepatitis C","volume":"32","author":"Buhler","year":"2012","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.medmal.2014.07.015_bib0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.coviro.2011.10.019","article-title":"Anti-HCV drugs in the pipeline","volume":"1","author":"Yang","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0075","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-na\u00efve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial","volume":"376","author":"Kwo","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2014.07.015_bib0085","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0090","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0095","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0100","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.medmal.2014.07.015_bib0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological adverse effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0110","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1478-3231.2012.02856.x","article-title":"Protease inhibitor-based triple therapy in chronic hepatitis C: guideline by the French association for the study of the Liver","volume":"32","author":"Leroy","year":"2012","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.medmal.2014.07.015_bib0115","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2013.07.051","article-title":"Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic HCV genotype 1 infection\u2014a randomized trial","volume":"145","author":"Poordad","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.medmal.2014.07.015_bib0120","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.gastro.2013.09.036","article-title":"HCV, Ribavirin, and anemia: a new dawn","volume":"145","author":"Pol","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medmal.2014.07.015_bib0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/cirrhosis","volume":"58","author":"Bruno","year":"2013","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2014.07.015_bib0130","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(12)60025-7","article-title":"Sustained virologic response (SVR) in prior peginterferon\/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)+PR: the PROVIDE study interim results","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0135","doi-asserted-by":"crossref","first-page":"S576","DOI":"10.1016\/S0168-8278(13)61429-4","article-title":"Safety and efficacy of boceprevir\/peginterferon\/ribavirin (BOC\/P\/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials","volume":"58","author":"Vierling","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2012.10.023","article-title":"The natural history of compensated HCV-related cirrhosis: a prospective long-term study","volume":"58","author":"Gomez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","article-title":"Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection","volume":"32","author":"Alazawi","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medmal.2014.07.015_bib0150","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","article-title":"The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients","volume":"43","author":"Sangiovanni","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.medmal.2014.07.015_bib0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.medmal.2014.07.015_bib0160","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/liv.12363","article-title":"Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1","volume":"34","author":"Salmon","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.medmal.2014.07.015_bib0165","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.medmal.2014.07.015_bib0170","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.medmal.2014.07.015_bib0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterol"},{"key":"10.1016\/j.medmal.2014.07.015_bib0180","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.23842","article-title":"Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C","volume":"52","author":"Roomer","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.medmal.2014.07.015_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir, an NS5 nucleotide polymerase inhibitor, with peginterferon alfa-2a and ribavirin intreatment-na\u00efve patients with hepatitis C genotypes 1, 4, and 6 infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.medmal.2014.07.015_bib0190","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2014.07.015_bib0195","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2014.07.015_bib0200","first-page":"12671","article-title":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial","author":"Pol","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.medmal.2014.07.015_bib0205","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1053\/j.gastro.2011.08.051","article-title":"Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C","volume":"141","author":"Zeuzem","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.medmal.2014.07.015_bib0210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.medmal.2014.07.015_bib0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.medmal.2014.07.015_bib0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.medmal.2014.07.015_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.medmal.2014.07.015_bib0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.medmal.2014.07.015_bib0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.medmal.2014.07.015_bib0240","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.medmal.2014.07.015_bib0245","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.medmal.2014.07.015_bib0250","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Eng J Med"},{"issue":"16","key":"10.1016\/j.medmal.2014.07.015_bib0255","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Eng J Med"},{"issue":"20","key":"10.1016\/j.medmal.2014.07.015_bib0260","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Eng J Med"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X14001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X14001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:13:03Z","timestamp":1759972383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X14001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0399077X14001929"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2014.07.015","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hepatitis C: Perspectives","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}